<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="109221">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01847664</url>
  </required_header>
  <id_info>
    <org_study_id>RIT-4/DIV</org_study_id>
    <nct_id>NCT01847664</nct_id>
  </id_info>
  <brief_title>Rifamycin SV-MMX® 400 mg b.i.d. vs. Rifamycin SV-MMX® 600 mg t.i.d. vs. Placebo in Acute Uncomplicated Diverticulitis</brief_title>
  <official_title>A Randomised, Double-blind, Double-dummy, Multi-centre, Comparative Parallel-group Study to Evaluate the Efficacy of Oral Rifamycin SV-MMX® 400 mg b.i.d. vs. Rifamycin SV-MMX® 600 mg t.i.d. vs. Placebo in the Treatment of Acute Uncomplicated Diverticulitis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Dr. Falk Pharma GmbH</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Dr. Falk Pharma GmbH</source>
  <oversight_info>
    <authority>Germany: Federal Institute for Drugs and Medical Devices</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the trial is to compare the efficacy of Rifamycin SV-MMX® 400 mg b.i.d. vs.
      Rifamycin SV-MMX® 600 mg t.i.d. vs. placebo in patients with acute uncomplicated
      diverticulitis.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>August 2013</start_date>
  <completion_date type="Anticipated">December 2015</completion_date>
  <primary_completion_date type="Anticipated">December 2015</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Rate of patients with treatment success at the day 10 visit</measure>
    <time_frame>10 days</time_frame>
    <description>Treatment success includes e.g.:
absence of diverticulitis related symptoms
no complications of acute diverticulitis
no hospitalisation due to acute diverticulitis</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>First visit with treatment success</measure>
    <time_frame>10 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of surgical intervention of acute diverticulitis</measure>
    <time_frame>10 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of hospitalisation due to acute diverticulitis</measure>
    <time_frame>10 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of occurrence of complicated diverticulitis</measure>
    <time_frame>10 days</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">375</enrollment>
  <condition>Uncomplicated Diverticulitis</condition>
  <arm_group>
    <arm_group_label>A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Rifamycin SV-MMX® 400 mg b.i.d.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Rifamycin SV-MMX® 600 mg t.i.d.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>C</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Rifamycin SV-MMX® placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rifamycin SV-MMX®</intervention_name>
    <arm_group_label>A</arm_group_label>
    <arm_group_label>B</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Signed informed consent,

          2. Patient is eligible for out-patient treatment,

          3. Men or women between 18 and 80 years of age,

          4. Diagnosis of left-sided uncomplicated diverticulitis confirmed by ultrasonography
             (US) and/or computed tomography (CT) according to modified Hinchey classification
             (stage 1a) or Hansen/Stock classification (stage I/IIa) or Ambrosetti classification
             (stage mild),

          5. Presence of significant left lower quadrant pain during the last 24 hours before
             baseline,

          6. CRP &gt; ULN and/or leucocytosis (&gt; ULN) at screening visit

        Exclusion Criteria:

          1. Existing complications of diverticulitis (diverticulitis with associated abscess,
             fistula, obstruction or perforation),

          2. Right-sided diverticulitis,

          3. Previous colonic surgery (except appendectomy, haemorrhoidectomy, and endoscopic
             removal of polyps),

          4. Chronic inflammatory bowel disease (such as Crohn`s disease, ulcerative colitis) or
             celiac disease,

          5. Presence of symptomatic organic disease of the gastrointestinal tract (with the
             exception of non-bleeding hemorrhoids or hiatal hernia),

          6. Hemorrhagic diathesis,

          7. Active peptic ulcer disease,

          8. Abnormal hepatic function or liver cirrhosis,

          9. Abnormal renal function,

         10. Colorectal cancer or a history of colorectal cancer,
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Tanju Nacak, Dr.</last_name>
    <phone>+49 (0)761 1514</phone>
    <phone_ext>187</phone_ext>
    <email>nacak@drfalkpharma.de</email>
  </overall_contact>
  <location>
    <facility>
      <name>Evangelisches Krankenhaus Kalk</name>
      <address>
        <city>Cologne</city>
        <state>Nordrhein-Westfalen</state>
        <zip>51103</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Wolgang Kruis, Prof. Dr.</last_name>
      <phone>+49 (0)221 8289</phone>
      <phone_ext>5289</phone_ext>
      <email>kruis@evkk.de</email>
    </contact>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>May 2014</verification_date>
  <lastchanged_date>May 14, 2014</lastchanged_date>
  <firstreceived_date>April 26, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Diverticulitis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Rifamycins</mesh_term>
    <mesh_term>Rifamycin SV</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
